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Common metabolic and endocrine alterations exist across a wide range of muscular dystrophies. Skeletal muscle plays an impor-
tant role in glucose metabolism and is a major participant in diﬀerent signaling pathways. Therefore, its damage may lead to
diﬀerentmetabolicdisruptions.Twoofthemostimportantmetabolicalterationsinmusculardystrophiesmaybeinsulinresistance
and obesity. However, only insulin resistance has been demonstrated in myotonic dystrophy. In addition, endocrine disturbances
such as hypogonadism, low levels of testosterone, and growth hormone have been reported. This eventually will result in conse-
quencessuchasgrowthfailureanddelayedpubertyinthecaseofchildhooddystrophies.Otherconsequencesmaybereducedmale
fertility,reducedspermatogenesis,andoligospermia,bothinchildhoodaswellasinadultmusculardystrophies.Thesefactsallsug-
gest that there is a need for better comprehension of metabolic and endocrine implications for muscular dystrophies with the pur-
pose of developing improved clinical treatments and/or improvements in the quality of life of patients with dystrophy. Therefore,
the aim of this paper is to describe the current knowledge about of metabolic and endocrine alterations in diverse types of dystro-
phinopathies, which will be divided into two groups: childhood and adult dystrophies which have diﬀerent age of onset.
1.Introduction
There are about 30 diﬀerent types of muscular dystrophies
caused by alterations in diverse genes, which are character-
ized by the progressive loss of muscle in accordance with
age of onset, severity, and the group of muscles aﬀected [1].
The altered protein in most of these dystrophies is located
in muscle ﬁber and is linked to other proteins, enzymes, or
extracellular matrix [2]. Myopathologies are associated with
diﬀerent ages of onset, for example, Duchenne muscular
dystrophy(DMD) and Becker musculardystrophy (BMD)as
well as Emery-Dreifuss muscular dystrophy (EDMD) dem-
onstrating their ﬁrst clinical manifestations during child-
hood [3], whereas some laminopathies such as myotonic
dystrophy or limb-girdle muscular dystrophy are developed
during adulthood [4]. This group of diseases can cause dif-
ferent physical symptoms such as contractures and scoliosis,
respiratory impairment, swallowing and feeding diﬃculties,
and, in some cases, metabolic alterations have been reported
[4, 5]. Even so, the primordial clinical sign is muscle weak-
ness [4, 5].
Skeletal muscle is responsible for 70–80% of whole body
insulin-stimulated glucose uptake, disposal, and storage;
therefore, this tissue is considered the major “player” in
energy balance [6]. Furthermore, skeletal muscle has inﬂu-
ence on the metabolism and storage of lipids and plays an
important role in hormone signaling in insulin sensitivity
[6]. Insulin receptors are localized in the cell membrane of
target tissues (liver, adipose tissue, and muscle ﬁbers) [7, 8].
It is important to emphasize that in dystrophinopathies the
cell membrane of myocytes is damaged [3]. We have hypoth-
esized that dysfunction of membrane of myocytes could alter
the insulin receptor function, and as a result an increase may
occur in the risk for developing insulin resistance. This fact
will be discussed later. Insulin resistance is an important fac-
tor for the development of type II diabetes and a risk factor
for cardiovascular disease, dyslipidemia, hypertension, and
obesity [6, 9]. The progression of muscular damage depends2 International Journal of Endocrinology
onproteinmutation[3].However,itisimportanttoconsider
thatmuscledamagemaybeagerelated.Theaimofthispaper
is to describe the current knowledge about of metabolic and
endocrine alterations in diverse types of dystrophinopathies,
which will be divided into two groups: childhood and adult
dystrophies which have diﬀerent age of onset.
2. Childhood Dystrophies
2.1. Clinical Characteristics of Duchenne/Becker Muscular
Dystrophy. DMD has an incidence of 1/3500 live male births
[10].Initialsymptomsbegininearlyinfancy,presentingwith
muscular weakness between 2 and 4 years of age [11]. This
appears when the patient begins to walk [12]. These hip
weaknesses will be manifested in an awkward walk with a
tendency to fall; later, stair climbing becomes diﬃcult [12].
A classic sign of muscular weakness is Gower’s sign, which
indicates weakness of the pelvic girdle muscles [11, 12]. Usu-
ally, joint contractures at the ankles and hips are increased
as the disease progresses [11, 12]. Finally, the development
of muscle atrophy leads to wheelchair dependency, which
typically occurs between 9 and 12 years of age [10]. The
susceptibility for lung infections increases and respiratory
capacity decreases [13]. Respiratory insuﬃciency appears at
∼14 years of age and may result in death at ∼25–30 years
of age [13]. Another cause of death may be cardiomyopathy,
which begins at ∼5y e a r so fa g ea n de v o l v e si nap a r a l l e l
manner with progression of the disease until this condition
eventually leads to the patient’s death [14]. Even so, car-
diomyopathy is responsible for ∼60–80% of deaths [14].
Eagle et al. [15] reported a mean age of death of 14.4
years in the US during the decade of the 1960s, and this value
increased to 25.3 years of age in 1990. Fortunately, advances
in the treatment of dystrophinopathies have improved life
expectancy because patients may reach adulthood in the
third and in some cases the fourth decade of life [15].
Becker muscular dystrophy (BMD) is clinically similar
to DMD but is a less severe form of myopathy, aﬀecting
1/30,000males[16].PatientswithBMDstarttoshowclinical
signs between 2 and 20 years of age. Compared to DMD,
progression in BMD is slower [17, 18]. Some BMD patients
present clinical signs similar to those of DMD, whereas some
patients are still able to walk at the age of 60 years [19].
Inability to walk prevails at about 30 years old, and death is
frequently present 30 years after the appearance of the ﬁrst
clinical signs [20]. Cardiomyopathy usually occurs in 73% of
BMD patients >40 years old [20].
Symptoms of Emery-Dreifuss muscular dystrophy
(EDMD) generally appear during the ﬁrst decade of life [21].
The principal clinical characteristics are contractures of the
neck extensor muscle, spine, Achilles tendons, and elbows
[22]. After muscle weakness, wasting appears during the end
of the second decade of life and begins in a humeroperoneal
distribution [23]. Cardiac complications begin at the end of
the second decade, and sudden cardiac death due to ven-
tricular dysrhythmia is common in this dystrophy [24].
DMD and BMD are X-linked diseases caused by muta-
tions in the DMD gene, which is responsible for encoding
dystrophin protein and is located at locus Xp21 [25–27].
Dystrophin protein is associated with an oligomeric protein
complex known as dystrophin-glycoprotein complex or
dystrophin-associated protein complex [28, 29]. The mecha-
nical function of the dystrophin-glycoprotein complex is to
stabilize the plasma membrane (sarcolemma) during the
stress of repeated contraction and relaxation cycles [30]. In
patients with DMD, dystrophin is absent in the sarcolemma,
whereas in BMD its expression is greatly reduced but is
still located in the sarcolemma [31]. Mutations (deletions,
duplications, point mutations) cause the lack or semilack of
dystrophin [32]. These mutations have many functional and
structural consequences in skeletal muscle, in DMD patients;
muscle biopsy characteristically demonstrates necrotic or
degenerating muscle ﬁbers [32]. These necrotic ﬁbers are
surrounded by macrophages. Small immature centrally
nucleated ﬁbers are also observed, reﬂecting muscle regen-
eration from myoblasts [31–33] that results in a balance
between necrotic and regenerative processes in the early
phase of the disease. Later, the regenerative capacity of the
muscles appears to be exhausted, and muscle ﬁbers are grad-
ually replaced by connective and adipose tissue (Figure 1)
[33].
EDMD is usually inherited as an X-linked recessive dis-
order, although an autosomal dominant form has also been
described [34]. This dystrophy is caused by mutations in
the gene for emerin (EMD gene) localized on chromosome
Xq28 [35]. Emerin is an integral serine-rich protein of the
nuclear envelope inner membrane, which is ubiquitously
expressed in most tissues and contains 254 amino acids [36].
The autosomal form of EDMD is caused by mutations in the
LMNA gene localized at chromosome 1q21.2-q21.3, which
encodes an A-type nuclear lamin [37]. This lamin is an inter-
mediate ﬁlament protein associated with the inner nuclear
membrane [38]. Emerin interacts with both lamin A and
laminCinthenucleus.Ithasbeenproposedthatthesemuta-
tions may result in increased nuclear fragility during mecha-
nical stress or increased susceptibility to apoptosis [39].
2.2. Endocrine System. The most important endocrine alter-
ation in DMD/BMD patients is hypogonadism, which has
been related to dystrophies [40]. Consequences of this state
are delayed puberty, growth failure, osteoporosis, and meta-
bolic abnormalities [40–42]. In 2008, Al-Harbi et al. [40]
measured total and free serum testosterone levels in 59 men
with diﬀerent dystrophinopathies. Results obtained showed
that 54% had low total testosterone, 39% had low total and
free values, and 8% had low free with normal total levels
[40]. In addition to Becker and Duchenne dystrophies (n =
12), other dystrophinopathies were included such as mono-
tonic dystrophy (n = 12), facioscapulohumeral dystrophy
(n = 11), metabolic myopathy (n = 7), and body myositis
(n = 17) [40]. Interestingly, there were no signiﬁcant diﬀer-
ences in the prevalence of hypogonadism among the various
forms of myopathy, even after considering age as a con-
founder [40]. It has been established that testosterone levels
decline with aging, and this is associated with decreased
muscle mass and strength in healthy subjects [43]. Testos-
terone treatmentincreases muscle mass and strength in olderInternational Journal of Endocrinology 3
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Figure 1:Histologyofnecroticskeletalmuscle.Image(a)showedanormalskeletalmusclefromquadricepsmuscle,characterizedbyhealthy
myoﬁbres with peripheral nuclei (PN). Skeletal muscle of control subjects was obtained from males without dystrophinopathies at 40 years
old. Image (b) showed a necrotic skeletal muscle from quadriceps muscle of a patient with DMD/DMB at ﬁve years old, characterized by
inﬁltrating inﬂammatory cells (ICs) and degenerating myoﬁbres (DMs). Transverse muscle sections stained with haematoxylin and eosin.
Scale bar represents 50m. This biopsy was obtained for the purpose of performing diagnostic.
hypogonadal males [44]. The importance of testosterone in
the maintenance of muscle mass is critical, and testosterone
therapy should be considered whenhypogonadism is present
[43, 44].
Growth hormone (hGH) has anabolic eﬀects in normal
skeletal muscle [45]. It has been suggested in only one study
that this hormone plays a role in the pathogenesis of DMD,
but there is insuﬃcient evidence to support that idea [45,
46].For instance, in one study, treatment with hGH was
administered to DMD patients, but no eﬀect was shown on
clinical status and natural history of DMD, either beneﬁcial
or detrimental [47]. In addition, Merlini et al. [45]d e m o n -
strated in DMD patients with impaired hGH secretion that
no association exists between diminished secretion of hGH
anddiﬀerentformsofthedisease.Interestingly,thereisacase
report of hGH treatment of a young male with DMD with
hGH deﬁciency who showed improved growth velocity and
motor function [45]. Controversies still exist about the
beneﬁt and the role of hGH and the resolution in regard to
treatment administration with hGH for counteracting short
stature. This treatment should be individualized with the
objective to obtain improved results [40].
No eﬀective treatment has yet been demonstrated to
amelioratethevariousconsequencesofmusculardystrophies
[48]. However, in recent years a range of approaches have
been developed to correct the genetic defect, restore func-
tional expression of dystrophin, slow disease progression,
and improve the quality of life for DMD patients [49]. Those
treatments can be categorized into three classes: genetic, cell-
based, and pharmacological approaches such as corticos-
teroids [50].
The use of pharmacological treatment with corticos-
teroids is justiﬁed by the fact that DMD is characterized by
aggressive inﬂammation, and there is strong evidence that
this contributes to myoﬁber necrosis [48, 51]. Until a cure
for DMD is found, treatment will involve administration
of corticosteroids combined with interventions to alleviate
cardiac and respiratory problems [51].
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Figure 2: Side eﬀects of glucocorticoid treatment in muscular
dystrophies.
However, it is important to note that corticosteroids have
a catabolic eﬀect on muscle (nonexercised muscle) and have
an eﬀect on preserving existing muscle ﬁbers and reducing
inﬂammation, even though their exact mechanism of action
in dystrophic skeletal muscle is unknown [12, 48]. Moreover,
use of glucocorticoids [GC] in patients with DMD and BMD
is common, but GCs have diﬀerent side eﬀects (Figure 2)
[48]. Two of the most important side eﬀects are growth fail-
ure and delayed puberty [52]. Currently, there are no studies
examining the outcomes of treating delayed puberty in
patients with DMD.
2.3. Metabolic Alterations. About a decade ago, clinical
researchers began to notice that patients with DMD tended
to present obesity [53]. However, it was necessary to demon-
strate the prevalence of obesity in children with DMD
because obesity had only been described from clinical expe-
rience [54]. For this reason, it was also necessary to measure4 International Journal of Endocrinology
body composition of these patients which, in turn, depended
on technology available [55].
With the advance in knowledge, it was observed that
DMD patients also develop malnutrition as a consequence
of the progression of the illness [56]. In the following para-
graphs, some metabolic issues will be described such as mal-
nutrition and obesity and, additionally, some abnormalities
in glucose metabolic pathway.
2.3.1. Malnutrition. In patients with dystrophinopathies,
nutrition is a problem to consider. It has been reported that
50% of DMD patients are underweight by the age of 18
[54]. Some studies have shown that this problem generally
is caused by feeding diﬃculties, gastrointestinal dysfunction,
and reduced weight gain [57]. It has also been observed that
chewing and swallowing diﬃc u l t i e si nb o t ha m b u l a n ta n d
nonambulant DMD patients are related to increased weak-
ness of masticatory muscles, malocclusion, and other abnor-
malities of the oropharyngeal process [58]. Additionally, gas-
tric distension has been reported in DMD and BMD, which
can contribute to delay gastric emptying, gastroesophageal
reﬂux, and subsequent nutritional disturbances [59].
Malnutrition has also been observed in patients with
DMD/BMD who are severely compromised by respiratory
failure [13]. This fact has been described in advanced stages
of those dystrophinopathies when breathing eﬀort increases
and, as a consequence, caloric requirements drastically
increase. Gonzalez-Bermejo et al. [13] showed that speciﬁc
nutritional measures should be taken when patients have
advanced forms of dystrophy, and mechanical ventilation
becomes necessary because, surprisingly, these patients have
balanced energy intakes and resting energy expenditure
(REE); hence, they are not likely to suﬀer from signiﬁcant
malnutrition. However, Gonzalez-Bermejo et al. [13]f o u n d
that 34% of patients aged 25 ± 4y e a r sw h oh a dr e c e i v e d
nocturnalmechanicalventilationhadadecreaseofREE.This
eﬀect was also observed in patients with DMD of diﬀerent
age groups (10-11 years; 12–14 years; 15–17 years; 18–29
years), where REE was signiﬁcantly lower than the value
obtained for healthy controls [13]. Both the low REE and the
low physical activity during the early teenage years result in
a low energy requirement and may be related to obesity that
frequently occurs in this age group [13]. In contrast, in later
stages of the disease, patients increase their basal physical
activity [60]. It is possibly due to the presence of respiratory
failure, may lead to a high energy requirement, and thus
becomes one of the risk factors for development of malnu-
trition [60]. Additionally, it is important to consider that
loss of the ability to self-feed in DMD/BMD patients is very
common [61] .T h el e n g t ho fm e a lt i m ea l s oi n c r e a s e sw i t h
age, ranging from a mean of 18min in younger patients to a
mean of 32min in older patients [62]. The increase in time
is probably related to a combination of increasing weakness
of the masticatory muscles and diﬃculties in chewing and
swallowing[62].Perhapsitwouldbeagoodchoicetointrod-
uce dietary modiﬁcations as cutting food into smaller pieces
and changing the texture to soft foods in order to facilitate
chewing and to reduce meal time [62].
2.3.2.Obesity. Aspreviouslymentioned,obesityisanimpor-
tant identiﬁed problem in patients with dystrophinopathies
[53]. Body mass index (BMI) is the most frequently used
indicatorinclinicalpracticeinordertomakethediagnosisof
overweight or obesity [63]. Nonetheless, the main limitation
of the BMI is that it does not discriminate between fat mass
andleanmass[64].Ithasbeenobservedthatindividualswith
a BMI within normal limits have fat mass measurements that
fall within values considered as obesity when these have been
measured with more precise methods [64]. Therefore, it is
necessary to measure fat mass through body composition. It
is possible to evaluate the general nutritional status by body
weight composition, which could be estimated by measures
such as skinfold thickness (ST), dual energy X-ray absorp-
tiometry (DXA), bioelectrical impedance analysis (BIA),and
magnetic resonance imaging (MRI) [65].
At the age of 7 years, obesity may occur in patients with
DMD, and by the age of 13 years prevalence is 54%, and dis-
tribution of body fat is centralized [54]. Moreover, Martigne
et al. [56] provided additional information about nutritional
status in DMD patients during diﬀerent ages. This group of
investigators studied the progression of nutritional status in
17 DMD patients born prior to 1992. Obesity was evaluated
usingGriﬃths&Edwardscharts.Accordingtoit,obesitywas
deﬁned by body weight/age ratio ≥151%. At the age of 13
years, those patients showed a prevalence of 73% for obesity
and 4% for underweight. At age 15–26 years, the prevalence
of obesity decreased to 47% and prevalence of underweight
increased to 34%. Also, obesity at the age of 13 years was
associated with later obesity, whereas normal weight status
and underweight in 13-year-old patients were predicted later
[56].
It has been observed that obesity contributes to the
progression of the disease by exerting extra force on already
weakened muscle groups, essentially decreasing mobility
[56]. Obesity also has implications on increased respiratory
i n v o l v e m e n ta sw e l la sp o o r e rp s y c h o s o c i a ld e v e l o p m e n t
[57]. There is one hypothesis that describes the positive asso-
ciation of loss of ambulation and obesity increment in DMD
patients [12, 13]. Although Martigne et al. [56] found no
relationbetweentheageofambulationlossanddevelopment
of obesity.
Generally, fat mass is higher in patients with dystrophy
than in healthy subjects [66]. Indeed, as the dystrophic pro-
cess advances with age, percentage of fat mass increases at
least during the ﬁrst two decades of life [67]. In fact, body
composition of DMD patients has been evaluated (by bio-
electrical impedance analysis and skinfold-thickness mea-
surement), and the results show that lean mass in DMD
(65.3%)waslower(between ∼12%and25%)thaninhealthy
children, whereas fat mass in DMD (31.9% versus 22%) was
higher than in control children [67]. Additionally, a positive
correlationwasfoundbetweenageandpercentageoffatmass
andanegativecorrelationbetweenageandpercentageoflean
mass [67]. The authors suggest that muscle may have been
replaced by connective tissue [67]. In this context, Zanardi
et al. [55] studied obese and nonobese children with DMD
and evaluated the alteration of body composition in boys
with DMD using magnetic resonance imaging. Only obeseInternational Journal of Endocrinology 5
children showed a markedly increased fat mass (>50%),
whereas nonobese children with DMD showed fat mass
values similar to healthy boys [55]. In both obese and nono-
bese children with DMD, the characteristic that was dramat-
ically reduced was muscle mass, showing a reduction of 27%
of muscle volume compared with control subjects [55].
It is important to emphasize that the advance in the
knowledge and development of new technologies for assess-
ing nutritional status has shown that patients with DMD
p r e s e n ta b n o r m a ln u t r i t i o n a ls t a t u ss u c ha so b e s i t yo rm a l -
nutrition as part of the natural course of DMD. These alter-
ations are related to advancing age because dystrophy pro-
gresses over the course of time.
2.3.3. Glucose and Insulin Metabolism. To date, relatively
little is known about metabolic alterations in patients with
DMD and BMD. However, there are studies that described
some disturbances in glucose metabolism, which include
reduced glycolytic substrates, reduced activity of glycolytic
enzymes, and defects in insulin receptor signal transduction
(Figure 3)[ 68].
Some studies have suggested that there are metabolic
diﬀerences in the skeletal muscle of patients with DMD and
healthy subjects [69]. For example, it has been proven that
the concentration of glycolytic substrate glucose, gluco-
neogenic amino acids such as glutamine and alanine and lac-
tate, a glycolytic product, is lower in DMD patients as com-
paredtocontrolsinskeletalmuscle[70].Also,thedecreasein
the concentration of lactate in the muscle of DMD patients
may be due to the reduction in anaerobic glycolytic activity
or lower substrate concentration [71]. As a result, the low
concentration of glucose metabolism substrates may be one
of the reasons for energy deﬁcit in DMD patients [72].
Nishio et al. also showed that glucose serum concentra-
tion in DMD patients is signiﬁcantly lower and is associated
with low creatine kinase activity. This fact may probably be
one of the causes of energy deﬁcit in DMD patients [72].
These ﬁndings also have a relationship with other causes
described in diﬀerent studies in which glycolytic enzymes
were found to have reduced activity in lactate dehydroge-
nase, aldolase, and pyruvate kinase from muscle biopsies
of DMD patients, supporting reduced anaerobic glycolytic
activity [68]. Those results are in agreement with the low
concentration of previously described glucose metabolism
substrates.
Although there are no reports describing whether DMD
patients present insulin receptor signal transduction alter-
ations, some studies have evaluated whether there is a defect
in insulin secretion or receptor [73]. These studies hypothe-
sized that the possible changes in the sarcolemma of skeletal
muscle cells could produce defects in insulin signaling [73].
This has been proposed because patients with diabetes
present skeletal muscle weakness that could lead to changes
in the sarcolemma as a result of defects in insulin receptor
internalization and processing that have been well described
in insulin resistance and diabetes [74]. Further research is
needed to clarify this hypothesis.
Thereareothertypesofevidencethathavedemonstrated
damage of the plasma membrane of myocytes of boys with
Plasma membrane
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Figure 3: Some aspects of impaired glucose metabolism in patients
with childhood muscular dystrophies. The damage in the glucose
metabolism, no matter the reason, may probably be one of the
causesforenergydeﬁcitinDMDpatients,andthislowenergycould
result in muscular weakness in muscular dystrophies.
DMD and BMD [75]. It is well known that membrane
properties depend on phospholipid composition [76]. A
signiﬁcant reduction has been observed in muscle biopsies
of DMD patients in some membrane components or phos-
pholipids such as total creatine, glycerophosphorylcholine,
phosphoryl choline, carnitine, choline, and acetate [68], and
lower levels of choline-containing compounds indicate
membrane abnormalities. Additionally, a lower ratio of tri-
methyl amides (TMAs) compared with healthy tissue has
been demonstrated in biopsies of DMD patients. TMAs
are constituents of phospholipid metabolism and cell mem-
branes, and decreased TMA is considered to be associated
with a lower number of cells and reduced rate of membrane
synthesis [77]. Decrease in TMA may reﬂect degenerative
changes in the muscles of patients with DMD, resulting
in alterations in signal transduction that take place in the
sarcolemma [77].
However, despite the above-mentioned evidence, scarce
information exists about the alterations in glucose and
insulin metabolism in DMD patients. There is only one
study by Freidenberg and Olefsky in which an oral glucose
tolerance test and the measurement of insulin binding on
erythrocytes were performed in DMD patients and age-
matched healthy males. The results of this study showed that
insulin binding in erythrocytes was 20–30% lower in DMD
patients than in healthy subjects. This diﬀerence indicated
al o w e ra ﬃnity of insulin to its receptor in erythrocytes in
DMD patients. This alteration may be present prior to the
development of insulin resistance, which may occur in
severely immobilized patients. One possible cause for this
fact is the increased progression of the dystrophy. Further-
more, in the same study, it was found that patients with
DMD had elevated levels of glucose and insulin in compari-
son to a healthy control group [73].6 International Journal of Endocrinology
Table 1: Clinical aspects, metabolic and endocrine issues on muscular dystrophies.
Age of onset Clinical
characteristics Metabolic issues Endocrine issues Clinical complications Life span
Childhood
Muscular
Dystrophy
DMD Early infancy
Muscle weakness
Gower’s sign Joint
contractures
Muscle atrophy
Obesity
Insulin resistance
Malnutrition
Hypogonadism
Delayed puberty
Low testosterone
level Growth failure
Wheelchair dependency
Loss of ability of
self-feeding Gastric
distension Respiratory
insuﬃciency
Cardiomyopathy
25–30
years old
BMD 2–20 years old
Variable:
4th or 5th
decade of
life
Adult
Muscular
Dystrophy
MD1 20–60 years
old
Myotonia Muscle
weakness
Obesity Insulin
resistance
Hyperinsulinemia
Hypertriglyc-
eridemia Glucose
intolerance
Hypogonadism
Oligospermia Low
testosterone levels
Reduced fertility
Erectile dysfunction
Testicular atrophy
Hypogammaglobulinemia
Pneumonia Cardiac
arrhythmias
Variable:
5th or 6th
decade of
life
MD2 ∼48 years old
In summary, in muscular dystrophies which have child-
hood age of onset, such as DMD and BMD, there are com-
mon and well known clinical characteristics and complica-
tions that lead the patient to death (Table 1). But also some
common metabolic and endocrine alterations have been
identiﬁed in both DMD and BMD. One of the most impor-
tant metabolic aspects is nutritional status. Obesity and mal-
nutrition have been identiﬁed in these dystrophinopathies.
Furthermore, there are some biochemical aspects that have
demonstrated an impaired glucose and insulin metabolism.
Moreover, these patients present hypogonadism, which is
important to emphasize that hypogonadism consequences
are related to the age of onset. For instance, since hypogo-
nadism is present in early infancy, these patients are going
to present delayed puberty and growth failure (Table 1).
However, since DMD/DMB patients have short life expect-
ancy, secondary consequences of hypogonadism such as
reduced fertility and oligospermia are less relevant.
3.Adult MuscularDystrophies
Clinical features in muscular dystrophies also can appear in
juvenile or adult age, and these phenotypes diﬀer depending
on mutation type [78]. Some muscular dystrophies in
juvenile or adult age include distal myopathy, Miyoshi and
Nonaka [79], inclusion body myositis (IBM) [80], facioscap-
ulohumeral muscular dystrophy (FSHMD) [81], oculopha-
ryngeal muscular dystrophy (OPMD) [82], distal myopathy
[83], myotonic dystrophy (MD, type 1 or type 2) [84], and
limb-girdle muscular dystrophy (LGMD 1B) [79]. However,
we focused this paper on two last dystrophies.
3.1. Clinical Characteristics of Myotonic Dystrophy and
LGMD. Myotonic dystrophy (MD) is the most common
inherited neuromuscular disease in adults, with a global
incidence of 1/8000 individuals [85]. Two types of MD exist:
type 1 (MD1) and type 2 (MD2) [85, 86]. MD1 is a chronic,
slowly progressive, highly variable inherited multisystemic
disease. MD1 results from an unstable (CTG) expansion in
3  UTR of the MD protein kinase gene (MDPK) at 19q13.3
locus [84]. MD2 is caused by an unstable expansion of a
CCTG tetraplet repeat in intron 1 of the ZFN9 gene localized
on chromosome 3q21.3 [84]. The phenotypes of MD1 and
MD2 have a broad spectrum of clinical signs that include
mainly myotonia and muscle weakness. The ﬁrst neuromus-
cular symptoms appear during a wide age range (20–60
years) [86]. Other clinical signs of these dystrophies include
cataracts prior to 50 years of age, cardiac conduction defects,
endocrine changes, testicular atrophy, insulin resistance, and
hypogammaglobulinemia [84]. In MD2, clinical features
appear in adulthood (median age 48 years) in contrast to
adult-onset MD1 and childhood onset [87]. The majority of
patients (63%) die between 50 and 65 years of age [86, 87].
Pneumonia and cardiac arrhythmias are the most frequent
primary causes of death, each occurring in 30% of patients,
which was much higher than expected for the general pop-
ulation [88].
Other types of dystrophy are LGMD, which describes a
heterogeneous group of muscle disorders characterized by a
predominant proximal distribution of limb-girdle, shoulder,
and hip weakness [79]. At least 15 diﬀerent genetic forms of
LGMD are now known [79]. The phenotypes begin during
early childhood to late adulthood [89]. The LGMD group is
still growing today and consists of 19 autosomal dominant
and recessive forms (LGMD1A to LGMD1G and LGMD2A
to LGMD2M) [84, 89]. The proteins involved are diverse and
include sarcomeric, sarcolemmal, and enzymatic proteins
[90].
3.2. Endocrine Alterations. Endocrine abnormities have been
reported in MD2 and MD1 patients (Figure 4), including
the alteration in testicular function such as hypogonadismInternational Journal of Endocrinology 7
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Figure 4: Endocrine abnormalities described in MD1/MD2.
leading to oligospermia [91], low levels of testosterone (T),
and reduced spermatogenesis [92], resulting in reduced male
fertility. In fact, hypogonadism may be a cause for erectile
dysfunction (ED), which has been demonstrated in 25% of
patients with MD1 [93]. The occurrence of ED is indepen-
dent of the patient’s age but may be related to other intrinsic
factors of MD1 such as disease duration and severity and
CTGexpansion[94,95].Also,thosepatientspresentelevated
levels of follicle-stimulating hormone (FSH) and reduced T
level in comparison to control subjects [92, 93, 96].
Hypogonadism is very common in males with myo-
pathies and involves both interstitial (androgenic) and tubu-
lar (spermatogenic) gonadal functions. In primary hypo-
gonadism, luteinizing hormone (LH) increases and T level
is reduced [93, 94]. In contrast, in compensated hypogo-
nadism, LH increases and T levels are normal [93].
Testicular atrophy is reported to be the most prominent
feature in ∼80% of MD1 patients [97, 98]. Testicles of MD1
patients are characterized by an increase in the number and
size of Leydig cells as well as tubular atrophy, hyalinization,
ﬁbrosis of the seminiferous tubules and reduced spermato-
genesis. It has been reported that 46% of MD1 patients show
hormonal evidence of interstitial gonadal failure [97, 99].
3.3. Metabolic Alterations
3.3.1.Malnutrition. AlthoughMDpatientsdemonstratedis-
orders of the oropharyngeal cavity, myotonia of the tongue
and pharynx, impaired pharyngeal contraction, and slowing
of esophageal peristalsis, to date, there have been no reports
regarding the malnutrition state related to MD [4]. Loss of
abilitytocutandmanipulatefoodleadstoalossoftheability
of a person with MD to ensure adequate nutrition [100]. In
this context it has been reported that 62% of patients with
MD1 do not meet their daily energy requirements according
to government recommendations: 55% of MD1 patients had
a fat intake higher than the acceptable macronutrient distri-
bution ranges [4]. Furthermore, 10% of the MD1 group of
patients were categorized as obese (BMI > 30) and 13% had
BMI values <18.5, which is in the underweight category [4].
Patients with MD1 have macronutrient and energy intake
deﬁciencies as well as an insuﬃcient intake of minerals (cop-
per, zinc, and calcium) [57]. However, there are no reports
regarding malnutrition in MD patients.
3.3.2. Obesity. In muscular dystrophy, plasma membrane is
damaged, generating myoﬁbers passing through cycles of
deterioration and regeneration until the end of its repair
capacity [25, 28–30]. This induces the muscle ﬁbers to be
susceptible to the development of necrosis and to be replaced
by ﬁbrous connective tissue and adipose tissue [30]. Fibrotic
tissue is still considered as lean tissue, so the increase in fat
mass may be considered as a reﬂection of fat involution in
muscles [30–32]. Myotonic dystrophy is linked to metabolic
syndrome including insulin resistance, increased fat mass,
and hypertriglyceridemia [58].
Progressive muscle loss associated with fat inﬁltration
will carry a decrease in motor function and an increase in
whole body fat mass index and regional fat-free mass index
[55, 56]. Therefore, there is a progressive worsening of dis-
ease leading to a decrease of the vital capacity as well as total
lung capacity and increases in fat mass [56]. MD1 patients
present lower regional (legs, arms, and trunk), fat-free mass
index (FFMI), and higher fat mass index (FMI) than healthy
individuals [101]. In MD1 patients, a correlation has been
reported with an increased total fat-free mass index and
decreased motor function and with both decreasing vital
capacity and total lung capacity [101, 102].
Aitkens et al. [103] observed that patients with neuro-
muscular disease showed more cases of obesity and were
more sedentary than control subjects (37% versus 34%).
However, in this study only 11 patients with neuromuscular
diseasewereanalyzed,andonlyfourofthepatientshadmyo-
tonic dystrophy [103]. Therefore, this is not the best refer-
ence to determine the prevalence of obesity in MD patients
[54]. Recently, Kaminsky et al. [102] studied 106 patients8 International Journal of Endocrinology
with MD1 (46 males and 58 females) within a range of
55 years of age. These authors reported that the prevalence
of obesity was 25.6% and hypertriglyceridemia was 47.6%
[102]. The increased fat mass in MD1 patients could be con-
sidered a reﬂection of fat involution in muscles and a link
with the metabolic disturbances in these patients [102].
3.3.3. Glucose and Insulin Metabolism. Patients with myo-
tonic dystrophy have alterations in glucose metabolism, and
it has been reported that these individuals have insulin resis-
tanceasanearlymanifestation[101].Insulinresistanceisthe
main cause of glucose intolerance in MD1 and, as a con-
sequence, hyperinsulinemia may coexist such as a compen-
satory mechanism and may later lead to the onset of diabetes
mellitus [101, 103].
However, the prevalence of diabetes mellitus in MD1
patients has not been proven. Muscle wasting and the low
physical activity can make worse insulin resistance and lead
to deregulation of protein catabolism [104].
Some hypotheses have been described to explain molec-
ular insulin resistance in MD patients. One hypothesis is
in regard to insulin receptor and the two existing isoforms:
isoformA(IR-A),whichlacksexon11,andisoformB(IR-B),
which includes exon 11 [105]. The insulin receptor B (IR-B)
predominates in insulin-responsive tissues such as skeletal
muscle. Interestingly, patients with MD1/MD2 express pre-
dominant insulin receptor isoform type A (IR-A) in skeletal
muscle [106]. With a histological evaluation of MD muscle
biopsies, it has been shown that the splicing changes in IR
precede histological abnormalities [105]. The results showed
that alterations in splicing occur prior to development of
dystrophic changes, and this abnormal splicing may be a
result of altered RNA binding due to the CUG expansion in
the DMPK gene [101, 106].
Another metabolic alteration associated with glucose is
abnormal insulin secretion in MD patients with normal
insulin sensitivity [101]. This suggests damage to the β-cell
secretory proﬁle. This damage was represented by increased
plasma proinsulin concentrations and a remarkably higher-
than-normal early secretory response after oral glucose
tolerance test in MD1 patients [107, 108]. A possible reason
for this abnormal insulin secretion may be related with the
protein kinase and the CUG expansion in the DMPK gene
[108]. Protein kinase is involved in the modulation of the
Ca+2 homeostasis in skeletal muscle cells, and Ca+2 homeo-
stasis is crucial for β-cell secretion events [109]. If the altera-
tion of calcium metabolism of the skeletal muscle also aﬀects
theβ-cell,thentheabnormalpatternofinsulinsecretionmay
be related to a malfunction of the MD1 protein kinase [109].
In summary, it has been reported that MD patients
present obesity with a prevalence of 25.6% and that it is
related to muscle atrophy. Obesity may be related to insulin
resistanceandmetabolicdisturbances.However,obesitydoes
not explain damage in glucose metabolism because in myo-
tonic individuals this metabolic alteration has been related
to CUG expansion in the DMPK gene, which causes splicing
changes in IR. This metabolic alteration has also been related
to problems with insulin secretion. Therefore, all types of
damage in glucose metabolism in MD patients are related
to the problem in the gene itself and not with the problems
caused by the pathology. In this context, in DMD it has
been noted that the metabolic problems are as a result of the
pathology, for example, damage in membrane permeability,
problems with glycolytic enzymes, lower glucose metabolism
substrates, and changes in the sarcolemma.
On the other hand, it is important to denote that in
adult muscular dystrophies such as MD, metabolic abnor-
malities aresimilar tothoseidentiﬁedin childhood muscular
dystrophies (Table 1). Additionally, in MD1 and MD2 some
endocrine alterations have been identiﬁed (Table 1). One
of these alterations is hypogonadism, which has also been
identiﬁed in childhood muscular dystrophies (DMD/BMD).
Inthiscase,sinceonsetisduring adulthood, theprimaryand
more relevant consequences of hypogonadism are related to
reduced fertility, reduced spermatogenesis, low testosterone
levels, and erectile disfunction. In contrast to DMD/BMD,
these patients had a normal growth and puberty.
4. Conclusions
Clinical and genetic characteristics of muscular dystrophies
are diverse but all have one common characteristic: muscular
atrophy. The muscle is one of the main tissues that regulates
lipid and glucose metabolism by hormones such as insulin.
It is important to consider that muscular dystrophies are
related to weakness, fatigue, decreased mobility, and reduced
physical working capacity. In addition to the muscular atro-
phy in these pathologies, replacement of skeletal muscle for
fat and ﬁbrotic tissue produces a reduction of the muscular
mass; therefore, there is an imbalance for all these tissue
functions. The combination of increased adiposity and
sedentary lifestyle increases the risk for the development of
metabolic syndrome. Age is an important factor in the mus-
cular dystrophies, which produces the diﬀerences in clinical
manifestation because age causes a more rapid progression
of clinical, metabolic, and hormonal problems. For example,
DMD patients often have short stature, whereas MD patients
do not have height-related issues. DMD/BMD patients are
frequently wheelchair-bound, and MD individuals do not
present this limitation. DMD patients have problems with
delayed puberty, whereas MD patients may have reproduc-
tive capabilities and have a functional sexual life. Metabolic
problems may also increase if clinical manifestations begin
in early age as in DMD and BMD. In this type of dystrophy,
obesity is observed in the ﬁrst decade, and during the course
of time these patients may show malnutrition, whereas MD
patients only develop obesity. Knowledge in regard to meta-
bolic, physiological, and molecular alterations in muscular
dystrophies will provide tools that will improve the quality
of life for these patients.
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